Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. develops and markets orthopaedic medical devices for the surgical treatment of bunions and related midfoot deformities. Its updates center on the Lapiplasty® 3D Bunion Correction procedure and related technologies used by surgeons, ambulatory surgery centers and hospitals.
Recurring news themes for TMCI include quarterly and annual financial results, revenue guidance, surgeon adoption, cash and liquidity updates, product introductions and clinical data. Company announcements also cover additions to the bunion and midfoot technology portfolio, including SuperBite™ Compression Screw System, Lapiplasty® Lightning™ technology, SpeedMTP® and IntelliGuide® PSI, as well as patent portfolio activity and presentations at foot and ankle surgery conferences.
Treace Medical Concepts (Nasdaq: TMCI) announced the first surgical case using its new Lapiplasty® Lightning™ technology, an enhancement of the Lapiplasty® System that adds advanced instrumentation and SpeedPlate® Rapid Compression Fixation to reduce steps, correct in three planes, and streamline workflow.
The company plans a limited market release midyear 2026 followed by full commercialization before year-end 2026. A surgeon on Treace's advisory board reported faster procedures with greater accuracy and no need for provisional fixation.
Treace Medical Concepts (Nasdaq: TMCI) announced that CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at ~7:30 am PT. A live webcast and replay of the fireside chat will be available on the company’s investor relations website at https://investors.treace.com/. The company also noted it routinely posts investor‑important information in its Investor Relations section and encourages investors to check the site regularly for updates.
Treace Medical (Nasdaq: TMCI) entered a new five-year senior secured loan arrangement providing up to $175 million in debt financing on Dec 18, 2025. The package consists of $60 million funded at close, $65 million additional term loan availability, and a $50 million revolving credit facility, each subject to conditions.
Proceeds prepaid the company’s prior $50 million term loan and $4 million drawn on its prior revolver. Interest equals applicable SOFR with a 3% floor plus 5.05% on the term loan (minimum ~8.05%) and 4.0% on the revolver (minimum ~7.0%). The term loan allows 48 months interest-only payments, extendable by 12 months. After the refinancing, Treace reports approximately $165 million of total liquidity (cash, equivalents, marketable securities, and unused facility availability), and listed Armentum Partners as financial advisor.
Treace Medical Concepts (Nasdaq: TMCI) will participate in two investor conferences on November 10–11, 2025. The company will appear at the UBS Global Healthcare Conference on Monday, November 10, 2025, with a fireside chat at 11:45 AM ET, and at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025.
A live webcast and replay of the UBS fireside chat will be available on the company’s Investor Relations website at https://investors.treace.com/. Treace routinely posts investor‑important information in the Investor Relations section at www.treace.com and encourages investors to check the site regularly.
Treace Medical Concepts (Nasdaq: TMCI) reported third quarter 2025 results on November 6, 2025 with revenue $50.2M (+11% YoY) and a net loss of $16.3M (or $(0.26) per share). Gross margin was 79.1%. Adjusted EBITDA loss improved 49% to $(2.6M). Total liquidity was $80.6M ($57.4M cash and marketable securities; $23.2M revolver availability).
The company released new 3D MIS and MTP fusion systems, presented positive clinical data, and expanded its patent portfolio to 122 granted and 194 pending patents. Treace cut full‑year 2025 revenue guidance to $211M–$213M (1%–2% growth) from $224M–$230M and now expects an Adjusted EBITDA loss of $6.5M–$7.5M for 2025, citing shifting surgeon preferences and softer elective procedure demand.
Treace Medical Concepts (NasdaqGS: TMCI) will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Company management will host a conference call at 4:30 PM ET the same day to discuss results and answer questions.
Investors must register to receive dial-in numbers and a unique PIN to join the call. A live webcast and archived replay will be available on the company’s investor relations site at https://investors.treace.com/. Treace also posts investor‑important information regularly in the Investor Relations section of its website.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company focused on bunion treatment, announced significant product innovations and clinical study updates at the 2025 AOFAS Annual Meeting. The company unveiled several new technologies including Nanoplasty®, Percuplasty™, SpeedMTP®, and IntelliGuide™ PSI, expanding their bunion treatment portfolio.
The ALIGN3D™ clinical study data showed promising results with low radiographic recurrence rates of 7.7% at 48 months and 4.8% at 60 months. The MTA3D™ study demonstrated early weight-bearing capabilities averaging 7.9 days and significant improvements in both midfoot and 3D bunion deformity correction at 12 months.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in bunion treatment, reported Q2 2025 financial results with revenue of $47.4 million, up 7% year-over-year. The company reduced its net loss by 18% to $(17.4) million and improved adjusted EBITDA by 58% to $(3.6) million.
Key developments include the full market release of three new bunion technologies: Nanoplasty®, Percuplasty™, and SpeedMTP® systems. The company's Align3D™ technology received validation through four-year clinical data publication. Treace maintains its 2025 revenue guidance of $224-230 million, projecting 7-10% growth, and expects to achieve breakeven Adjusted EBITDA for full-year 2025.
The company's financial position includes $90.7 million in total liquidity, with cash usage decreasing by 55% in Q2 2025 compared to the prior year.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company focused on bunion and midfoot deformity treatments, will host an Investor Day on September 3, 2025, at 9:00 am ET in New York.
The event will feature presentations from management and experienced surgeons who will share their experiences with the company's expanded technology portfolio. Interested investors can register through investor relations by August 27, 2025. A live webcast and replay will be available on the company's investor relations website.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in bunion surgery solutions, has published four-year interim results from its ALIGN3D™ multicenter prospective study in the Journal of Foot & Ankle Surgery. The study, which followed 139 of 173 patients, demonstrated strong outcomes for the Lapiplasty® Procedure.
Key findings include an early return to protected weight bearing at 7.7 days, transition to athletic shoes at 6.5 weeks, and notably low recurrence rates of 0.8% using HVA>20° and 8.4% using HVA>15° at 48 months. Patient outcomes showed significant improvements, with an 81% reduction in pain and 89% improvement in walking/standing capabilities through the 48-month period.